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Abstract
Background:  The role of cortisol and its increased action/availability is implicated in the
pathogenesis of insulin resistance associated with obesity and metabolic syndrome but the
mechanism of increased action/availability is not known. Availability of several other lipophilic
hormones, drugs and pollutants are also reported to be increased in obesity. Increased lipids in the
circulation are reported to alter the fluidity and permeability of membranes. Hyperlipidemia is also
reported to alter the pharmacokinetics and pharmacodynamics of lipophilic molecules and also
membrane fluidity and permeability. In this context we assumed that the hyperlipidemia associated
with human obesity might play a role in the altered action/availability of cortisol and this in turn
might have initiated the metabolic complications. To evaluate our assumption we have
administered dexamethasone [low [50 µg/kg/day] or high [250 µg/kg/day] dose] to high-fat
[coconut oil & vanaspati] fed rats and the results were compared with rats administered with either
dexamethasone or high-fat.
Results and Discussion: Within two weeks, the rats co-administered with high-fat and
dexamethasone developed severe hyperglycemia, hyperlipidemia and insulin resistance compared
to rats treated either of them alone. High-fat fed rats treated with higher dose of dexamethasone
were presented with severe hyperglycemia, insulin resistance and also severe glycosuria. The
hyperlipidemia caused by high-fat feeding might have altered the transport and distribution of
dexamethasone, probably by altering the physical state of membranes and transport proteins.
Conclusion: From the results obtained, it can be speculated that the altered lipid and cortisol
metabolism could affect one another, forming a vicious cycle.
Background
Type 2 diabetes, obesity and metabolic syndrome are
emerging at an alarming rate worldwide [1-3]. Developing
societies worldwide shifting away from an agrarian exist-
ence to the current environment of high energy consump-
tion, minimal physical activity and a lifestyle that include
stress and anxiety are some of the several factors impli-
cated in the development of these disorders [4-8]. The
fundamental aspect in the etiology of these disorders is
insulin resistance and it is linked to a wide array of other
complications including gestational diabetes and poly-
cystic ovarian syndrome [3,9,10]. Insulin resistance is a
disorder in which target cells fail to respond to ordinary
levels of circulating insulin, hence higher than normal
concentrations of insulin are needed in order to maintain
normoglycemia. In response, more and more insulin is
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produced by the pancreas, leading to hyperinsulinemia.
The main characteristics of insulin resistance are uncon-
trolled lipolysis in adipose tissue, impaired uptake of glu-
cose by muscle and uncontrolled gluconeogenesis in the
liver. Over time, β cell compensation for the insulin resist-
ance fails, resulting in a progressive decline of β cell func-
tion which leads to type 2 diabetes [3,11]. In the past
decade, a large number of endocrine, inflammatory, neu-
ral, cell-intrinsic pathways and fatty acid composition/
metabolism have been shown to be dysregulated in obes-
ity causing insulin resistance [6,12,13]. Although it is pos-
sible that one of these factors plays a dominant role, many
of these factors are interdependent, and it is likely that
their dynamic interplay underlies the pathogenesis of
insulin resistance. Understanding the biology of these sys-
tems will inform the search for interventions that specifi-
cally prevent or treat insulin resistance and its associated
pathologies [12].
Increased free fatty acid [FFA] concentration, whether due
to increased endogenous mobilization or post absorptive
lipolysis on a fat-rich diet, is associated with insulin resist-
ance and β cell dysfunction, making them a likely culprit
[13,14]. There is now growing evidence that the original
theory [Randle or glucose-fatty acid cycle] supposing that
the decreased glucose uptake in muscle is a result of
increased fatty acid oxidation and suppressed glucose oxi-
dation cannot completely explain all experimental data
[15,16]. The metabolic defect reported involves early insu-
lin signaling pathways and is independent of FFA oxida-
tion [17]. Fatty acid composition in the diet is another
mechanism implicated in the development of insulin
resistance [6]. Replacing saturated fatty acids in the diet
with either monounsaturated fatty acids or polyunsatu-
rated fatty acids resulted in changes in serum fatty acid
profile and improved insulin sensitivity [18,19]. This
improvement in insulin sensitivity was found particularly
only in subjects with a relatively low fat intake [below
median 37% energy] [18,19]. Recent reports suggest that
the role of increased lipids in the development to type 2
diabetes is a secondary phenomenon, pathogenesis of dia-
betes primarily established by involving genetic and envi-
ronmental factors [20].
Several environmental factors, including high-fat diet, are
reported to activate the functioning of the hypothalamus-
pituitary-adrenal axis [HPA]. Frequently evoked HPA-axis
secretes excessive amount of cortisol [8,21] and elevated
cortisol level is implicated in the development of entire
spectrum of the metabolic syndrome, including insulin
resistance, visceral obesity and dyslipidemia as well as the
kinds of cardiovascular co morbidities that result
[8,21,22].
Half a century ago, Jean Vague have suggested that the role
of over activity of pituitary-adrenal axis, greater abun-
dance/stronger action of cortical steroids and its anti-insu-
lin effect, in the development of android [visceral] obesity
and its complication while gynoid obesity is free of these
effects and the circulation of lipids is also effected more
slowly [23]. Now there are several studies suggest that fre-
quent stress or perturbed secretion of cortisol in the devel-
opment of visceral obesity, insulin resistance and its
pathologies [8,21]. Glucocorticoids bring about their
multiple effects by activating the intracellular glucocorti-
coids receptor that binds to specific glucocorticoids-
responsive elements in the vicinity of regulated genes and
subsequently affect their expression. It is estimated that
glucocorticoid receptors can interact as transcription fac-
tors as many as 30% of genes, so it is not surprising that
glucocorticoids induce a wide range of responses [24].
Glucorticoids oppose the insulin-mediated inhibition of
hepatic glucose release [i.e. stimulate gluconeogenesis]
and decrease glucose use in muscle [4].
Although there are several reports suggest the role of glu-
cocorticoids in the development of insulin resistance and
its complications, its path physiological contribution to
idiopathic human obesity and its associated metabolic
complications has been the subject of long debate, domi-
nated by discussion of the inconsistent changes that occur
in plasma cortisol levels [25]. This controversy is
explained by the increased clearance and increased intrac-
ellular action/availability of cortisol independent of its
plasma levels [26-28]. The altered level or action of corti-
sol in obesity have been explained by the altered expres-
sion of the enzyme 11 β-hydroxysteroid dehydrogenase
type 1 [11 β-HSD1] in adipose tissue which generate cor-
tisol from inactive corticosterone [28], but the levels of
expression and activity of 11 β-HSD1 are debated in the
literature [28,29]. And this enzyme is exquisitely regulated
including by feeding, and it might be a key component in
the homeostatic adaptation to variations in macronutri-
ent intake [24,30]. Although the role of cortisol and its
increased clearance, action/availability are generally
accepted in the pathogenesis insulin resistance [8,26-
28,30], the mechanism involved in the altered action/
availability is not known.
Apart from cortisol, several other sex steroids are also
reported to be decreased in obesity or its clearance is
reported to be increased [31-33]. It is well known that
lipophilic molecules tend to accumulate in fat organs, a
phenomenon called "bioaccumulation" [5]. This have
been demonstrated using the unmetabolizable lipophilic
compound [2,4,5,2',4' 5'-Hexachlorobiphenyl [6-CB] – a
polychlorinated biphenyl] in rats [34]. Once adminis-
tered, this compound disappears with a half-life of half a
life span of the rats by fecal excretion and its accumulationInternational Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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is proportional to the adipose tissue mass. Although
unmetabolizable lipophilic molecules tend to accumu-
late, the metabolizable lipophilic-drugs are prevented
from accumulation by intracellular drug metabolizing
enzymes [34]. It is not known whether this theory is
applied to exogenously administered or endogenously
produced lipophilic steroid hormones.
Studies have shown that changes in lipid profile [i.e.
caused by hormonal variations, weight gain, diet, medica-
tion, illness & including normal biological fluctuations]
alter the phamacodynamic and pharmacokinetic of
lipophilic drugs [35-37]. A recent study has shown that
the pharamacological activity of the lipophilic drug [Cloz-
apine] is potentiated by hyperlipidemia, by facilitating its
blood brain barrier permeability [35].
Several reports have also shown that altered cortisol
metabolism affect lipid metabolism and altered lipid
metabolism affect cortisol metabolism [4,30], vice versa.
But it is not known whether altered cortisol metabolism
precede the obese state related complications or excess
body fat precede the altered cortisol metabolism [22].
Most of the available works deals these two states such as
altered cortisol metabolism [8,21] and altered lipid
metabolism [13] as two different etiological factors in the
development of obesity, insulin resistance and its related
disorders. But these two factors are associated in several
pathological conditions such as obesity, metabolic syn-
drome, gestational diabetes, polycystic ovarian syndrome
and type 2 diabetes [9,10,26,38].
Though glucocorticoids are helpful in adapting to short-
term stress, excessive glucocorticoid action becomes mala-
daptive, particularly if this excessive action occurs in the
absence of starvation [24]. This have been demonstrated
in rats administered parenteral nutrition, that the insulin
resistance caused by Dex is reduced significantly when the
fat/calorie content of parenteral nutrition is reduced to
50% of the adequate level [39]. Modern lifestyle increases
the likelihood of individuals eating more than they need
and the affluent sedentary lifestyle leads to sustained pos-
itive caloric balance [3]. In many of the developed socie-
ties, there is also a high level of perceived stress [8]. The
simultaneous presence of the sustained increase of lipids
in the circulation and chronic/repeated stress induced
secretion of cortisol is very much possible in the modern
world [8]. Cortisol is a lipophilic hormone [40] and obes-
ity is mostly associated with dysregulation of lipid metab-
olism [3]. From these observations we have assumed that
the hyperlipidemia associated with positive caloric bal-
ance or obesity might have facilitated the intracellular
action/availability of cortisol, which in turn might have
involved in the pathogenesis of insulin resistance and its
related disorders.
So we planned to study the combined effect of altered
lipid and cortisol metabolism, to know if there is any syn-
ergistic or interaction between the two, and their effect in
the development of insulin resistance. To know the com-
bined effect of altered lipid and cortisol metabolism, we
have administered the cortisol analog [Dexamethasone]
Dex to high-fat [coconut oil & vanaspati] fed Wistar rats.
Dex has been administered at varying dose and duration
by several studies to induce insulin resistance [41,42]. We
have selected two doses of Dex [low dose: 50 µg/kg/day
[41] and a high dose: 250 µg/kg/day] in our study. We
have used coconut oil [43] and Indian vanaspati [44] to
induce hyperlipidemia, as they are good source of satu-
rated and trans fatty acids. To control the daily intake of
fat, we have administered the high-fat via gavage [45]. We
planned to continue the treatment for 12 weeks, but sur-
prisingly, all the high-fat fed rats treated with higher dose
of Dex [250 µg/kg/day] developed severe glycosuria and
polyuria on fourteenth day of treatment. During the
experimental days we have analyzed the body weight,
food and water intake, and upon seeing the glycosuria on
14 day, we have analyzed the lipid profile, insulin resist-
ance and oral glucose tolerance test. The combined effects
of Dex and high-fat in the development of insulin resist-
ance and hyperglycemia were correlated with its individ-
ual effects and the results were related with other similar
pathological and experimental situations.
Methods
Animals
Male Albino rats, Wistar strain of body weight ranging
250–300 g bred in Central Animal House, Rajah Muthiah
Medical College, Tamilnadu, India, fed on laboratory diet
[Agro Corporation Private Limited, Bangalore, India] were
used for the study. Water and food was given ad libitum.
The standard pellet diet comprised 21% protein, 5% lip-
ids, 4% crude fiber, 8% ash, 1% calcium. 0.6% phospho-
rus, 3.4% glucose, 2% vitamin and 55% nitrogen free
extract [carbohydrates]. The fatty acid composition of
vanaspati is follows: 14:0-0.9, 16: 0-38.5, 18: 0-5.2, 18:1
trans n-9-16.2, 18:1 cis 34.0 and 18:2 n-6-5.0 and the fatty
acid composition of coconut oil is as follows: 14:0-48.9,
16:0-21.96, 18:0-6.0, 18:1-18.2, 18:2 [ω-6]-5.33 [43,44].
The animals were housed in plastic cages under controlled
conditions of 12 h light/12 h dark cycle and at 24 ± 2 °C.
The animals used in the present study were maintained in
accordance with the guidelines of the National Institute of
Nutrition, Indian Council of Medical Research,
Hydrabad, India and approved by the Animal Ethical
Committee, Annamalai University, Tamilnadu, India.
Dexamethasone sodium phosphate and insulin were pur-
chased from Sigma-Aldrich. Coconut oil and Indian
vanaspati [brand name DALDA] were purchased from the
local market, Chidambaram, India. All the other chemicalInternational Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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and biochemical used for the experiments were of analyt-
ical grade.
Preparation of fat emulsion: Fat emulsion was prepared
according to the method described [45] with some modi-
fications. A constant volume of 100 ml fat emulsion con-
taining 40 ml vanaspati, 30 ml coconut oil, 10 ml Tween
80, 5 ml propylene glycol and 15 ml distilled water, this is
stored at 4 °C. This was considered as high-fat emulsion
in this study and it was shaken before every use to ensure
homogeneity.
Experimental design
The animals were divided into 6 groups of 12 rats each
and housed 6 rats per cage.
Group I [Control]: Rats given laboratory diet.
Group II [HF]: Rats were given 5 ml of high-fat emulsion.
Group III [HF-LD]: Rats were given 5 ml of high fat emul-
sion and Dex at a dose of 50 µg/kg/day.
Group IV [HF-HD]: Rats were given 5 ml of high-fat emul-
sion and Dex at a dose of 250 µg/kg/day.
Group V [LD]: Rats were given Dex, at a dose of 50 µg/kg/
day.
Group VI [HD]: Rats were given Dex, at a dose of 250 µg/
kg/day.
Dex dissolved in saline was administered subcutaneously
[41]. The oral feeding of high-fat or water was started
gradually from 1 ml to 5 ml in the first five days, to allow
the rats to adapt to the high-fat feeding, and fixed at 5 ml
on the fifth day of the experiment and the same is contin-
ued daily throughout the experiment, but the Dex admin-
istration was started from the first day of fat feeding
onwards. Rats not receiving high-fat were given equal vol-
ume of drinking water using intra-gastric tube and rats not
receiving Dex were administered equal volume of normal
saline. All the rats were observed daily for the presence
any clinical symptoms. Food intake, water intake and
body weight changes were observed during the course of
the experiment. Urine output was measured by collecting
the urine in metabolic cages; the urine was collected under
a layer of toluene. On the fourteenth day of the experi-
ment the rats in the HF-HD groups were presented with
severe glycosuria and polyuria. The glycosuria was con-
firmed by Benedict's qualitative test. Following the obser-
vation of glycosuria on the 14th day of Dex treatment in
the HF-HD rats, OGTT and euglycemic clamp were con-
ducted on the subsequent days.
Oral Glucose Tolerance Test
After 14 days of Dex administration [i.e, on 15th day], the
rats were fasted overnight and OGTT was conducted in six
rats from each group, by administering glucose [3 g/kg]
with intra-gastric tube. Blood samples were obtained from
tail vein at 0, 30, 60, 90, and at 120 min after glucose
administration for the estimation of insulin and glucose.
Insulin was determined by rat insulin enzyme linked
immonosorbant assay [ELISA, kits, LINCO laboratories]
and glucose was determined by assay kit [Erba diagnos-
tics, Mannheim, Germany]. An "insulinogenic index",
defined as the ratio of the change in circulating insulin to
the change in the corresponding glycemic stimulus [46]
was calculated using the equation, [30-min plasma insu-
lin – Fasting Plasma Insulin]/[30-min plasma glucose –
Fasting Plasma Glucose], the final unit is expressed as
pmol/mmol [47].
Euglycemic clamp study
The remaining six rats from each group were used for eug-
lycemic clamp study. The rats were anaesthetized by giv-
ing intra peritoneal injection of amobarbital sodium [25
mg/kg]. Under anesthesia, euglycemic clamp was con-
ducted by cannulating in the jugular vein for the infusion
of glucose and insulin. 10% glucose and insulin 1 IU/ml
was administered [48] to keep the blood glucose in a
steady state [140 mg/dl], the rate of glucose infusion was
continuously adjusted while the insulin infusion was kept
constant. Glucose infusion rate [GIR] [mg/kg/min] was
measured under homeostasis five times during the exper-
iment at 15 minutes intervals. Glucose levels were deter-
mined by glucometer [One touch-horizon-Lifescan. Inc.]
[49]. Finally the rats were sacrificed by cervical decapita-
tion and blood drawn for the separation of plasma.
Plasma was stored at -80°C till the analysis. Total choles-
terol [T.Cho] and triglycerides [Tgl] were estimated by
assay kits [Erba diagnostics, Mannheim, Germany]. And
high density lipoprotein cholesterol [HDL] was analyzed
in the supernatant obtained after precipitation of the
plasma with phosphotungstic acid/Mg2+. Plasma low-
density lipoprotein cholesterol [LDL] was calculated from
total cholesterol, HDL and Tgl values using the Friedwald
equation [50] Plasma free fatty acid concentration was
estimated by the method of Falholt et al. [51]. Statistical
analysis was done by analysis of variance [ANOVA] fol-
lowed by Duncan's multiple range test by means of the
SPSS version 9.0 for Windows. P" value of less than 0.05
was considered to be statistically significant.
Results
Administration of Dex [both low and high dose] to high-
fat fed rats [HF-HD and HF-LD] have caused severe hyper-
glycemia, hyperinsulinemia, altered lipid profile, reduced
food intake, decreased insulinogenic index and GIR com-
pared to the corresponding Dex [HD and LD] or high-fatInternational Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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alone treated rats [Fig. 1 and Table 1, 2 &3]. The effects
were more pronounced and frank hyperglycemia with gly-
cosuria [urine sugar 2+ and above] was noted in all the
HF-HD rats on the 14th day of the Dex treatment.
Administration of high-fat [HF] or higher dose of Dex
[HD] decreased the food intake significantly when com-
pared to control rats, but it was unaltered in the low dose
Dex treated [LD] rats. When compared to HF and HD rats,
the reduction in food intake was more pronounced in the
HF rats. Administration of Dex together with the high-fat
[HF-HD & HF-LD] reduced the food intake further when
compared to the corresponding Dex alone treated [HD &
LD] or HF alone treated rats. The reduction in food intake
was more significant in the HF-HD rats compared to HF-
LD rats [Table 1]. Body weight was reduced significantly
after 14 days of Dex treatment in the HF-HD rats [data not
shown] while no significant differences were observed in
the other groups compared to control. The urine output
was increased three fold in the HF-HD rats compared to
control. The water intake remained unaltered in the HF
and LD rats when compared to control, but it was
increased significantly in the HD, HF-LD and HF-HD rats.
The increase in water intake was more pronounced in the
HF-HD rats compared to other groups [Table 1].
Figure 1 shows the glucose and insulin values during
OGTT. Fasting glucose was not altered between control
and HF rats, but it was increased significantly in the HD
and LD rats and the increase was directly proportional the
dose of Dex used. The dose dependent effect of Dex on
fasting glucose was further increased when the same dose
was given to high-fat fed [HF-HD and HF-LD] rats com-
pared to corresponding Dex [HD & LD] or HF alone
treated rats [Fig. 1]. Polyuria with urine sugar more than
2+ was noticed in all the HF-HD rats while no such obser-
vations were made on any other groups. The criteria for
diabetic type are a peak plasma glucose concentration >
16.8 mmol or 120-min post load plasma glucose concen-
tration > 11.2 mmol. According to this criterion, HF-HD
rats become severe diabetic on the 14th day of treatment
[52].
Although the fasting glucose was not increased in the HF
rats the fasting insulin was increased significantly in the
HF rats compared to control. Dex treatment increased sig-
nificantly the fasting insulin values in the HD and LD rats
compared to control, the increase was directly propor-
tional to the Dex dose [Fig. 1]. When compared to HF rats
the fasting insulin was increased more significantly in the
Dex treated [HD & LD] rats. The dose dependent increase
in fasting insulin was further increased when the same
dose of Dex was administered to high-fat fed [HF-HD and
HF-LD] rats [Fig. 1].
Administration of high fat [HF] or Dex [HD & LD] to Wis-
tar rats decreased the insulin sensitivity as shown by
reduced GIR, and reduced the insulin response, as shown
by reduced insulinogenic index, significantly when com-
pared to control rats. The decrease in insulinogenic index
and GIR were more significant in the Dex [HD & LD]
treated rats compared to HF rats. Administration of Dex
dose dependently decreased insulinogenic index and GIR
in the [HD & LD] rats, but the same dose further decreased
the GIR and insulinogenic index when administered to
high-fat fed rats [HF-HD & HF-LD] [Table 2].
High-fat [HF] feeding induced severe hyperlipidemia as
shown by increased FFA, Tgl, T.Cho, LDL and decreased
HDL when compared to control rats. Dex treatment also
increased the hyperlipidemia as shown by increased FFA,
Tgl, T.Cho, and LDL and reduced HDL in the HD and LD
rats compared to control. When compared between HF
and Dex treated [HD & LD] rats, FFA was increased, Tgl
was unaltered, HDL decreased in the HD rats, and all
other values were increased in HF rats [Table 3]. Dex dose
dependently alerted the lipid profile values [HD and LD],
but the same dose altered the lipid values further when it
Table 1: Changes in the food intake and water intake of control and experimental animals.
Control HF HF-HD HF-LD HD LD
Food intake (g/Week) 112.5 ± 8.5a 89.7 ± 6.5c 20.5 ± 1.5e 70.0 ± 5.6d 99.5 ± 7.5b 113.5 ± 8.6a
Water intake (ml/24 h) 31.5 ± 2.34a,b 31.01 ± 2.1a,b 114.56 ± 8.39d 36.29 ± 3.40c 34.60 ± 4.28b,c 30.50 ± 5.10a
Values are mean ± SD of 6 experiments in each group. Values not sharing common superscripts differ significantly at P ≤ 0.05.
Table 2: Changes in the Insulinogenic index and GIR or control and experimental rats
Control HF HF-HD HF-LD HD LD
GIR (mg/kg/min) 24.50 ± 1.85a 17.85 ± 1.29b 2.85 ± 0.02f 8.85 ± 0.64e 10.98 ± 0.79d 14.87 ± 1.08c
Insulinogenic index (pmol/mmol) 139.30 ± 10.13a 94.34 ± 6.87b 30.52 ± 2.21f 44.52 ± 3.24e 56.81 ± 4.12d 68.54 ± 4.9c
Values are mean ± SD or 6 experiments in each group. Values not sharing common superscripts differ significantly at P ≤ 0.05.International Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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was administered to high-fat fed [HF-HD and HF-LD] rats
[Table 3].
Discussion
Administration of Dex has been reported to induce insu-
lin resistance and hyperglycemia in animal studies
[41,42]. Our results shows that the hyperglycemic effect of
Dex have been potentiated/aggravated when it was
administered to high-fat fed [HF-HD and HF-LD] rats
compared to Dex alone [HD or LD] treated rats. The indi-
vidual effects of Dex [HD or LD] or high-fat [HF] is very
minimal with respect to hyperglycemia, hyperinsuline-
Table 3: Changes in the lipid profile of control and experimental animals
Control HF HF-HD HF-LD HD LD
FFA (mmol/l) 0.29 ± 0.02f 0.81 ± 0.03d 3.91 ± 0.29a 1.61 ± 0.11b 1.41 ± 0.99c 0.62 ± 0.04e
Tgl (mmol/l) 1.48 ± 0.08e 3.26 ± 0.13c 7.69 ± 0.80a 4.41 ± 0.9b 3.29 ± 0.28c 2.94 ± 0.18d
T.Cho (mmol/l) 2.12 ± 0.13f 4.42 ± 0.25c 5.68 ± 0.21a 4.96 ± 0.21b 3.85 ± 0.19d 3.08 ± 0.29e
LDL (mmol/l) 0.71 ± 0.02e 2.98 ± 0.07b 3.63 ± 0.09a 3.51 ± 0.08a 2.51 ± 0.88c 1.75 ± 0.06d
HDL (mmol/l) 1.11 ± 0.04a 0.78 ± 0.38b 0.51 ± 0.38e 0.63 ± 0.41d 0.68 ± 0.31c 0.75 ± 0.28b
Values are mean ± SD or 6 experiments in each group. Values not sharing common superscripts differ significantly at P ≤ 0.05.
Changes in glucose and insulin values during OGTT of control and experimental groups Figure 1
Changes in glucose and insulin values during OGTT of control and experimental groups. Values are mean ± of 6 experiments in 
each group. Values not sharing common superscript differ significantly at P ≤ 0.05.International Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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mia, hyperlipidemia, GIR and insulinogenic index when
compared to rats co-administered with Dex and high-fat
[HF-HD or HF-LD] [Table 1, 2,3 and Figure. 1].
Reports have shown that high-fat fed animal tend to eat
less compared to rats fed normal diet [53,54]. We have
also found a reduction in food intake in the HF rats com-
pared to control [Table 1]. Glucocorticoids are reported to
have dual metabolic action on food intake and body
weight gain which depends on the dose used [55]. At high
dose, it decrease the food intake and body weight, in con-
trast at lower dose it increase the appetite [42,55]. Similar
findings were observed in the HD rats, while in the LD rats
food intake was not increased but consumed the same
amount as that of control, which might be due to the var-
iations in the dose used.
Severe metabolic complications were observed in the HF-
HD rats, which might be responsible for the loss of body
weight and increased water intake observed in HF-HD rats
compared to HD, HF-LD, LD, and HF rats [Table 2]. The
food intake was reduced in the HD, HF-LD and HF rats,
but body weight was not affected. High-fat feeding might
have compensated the energy loss due to reduced food
intake in the HF and HF-LD rats. In the HD rats, the met-
abolic complications are significantly less when com-
pared to HF-HD rats, and the duration of the study is also
very short to show any minimal changes in the body
weight [Table 1]
Hyperlipidemic effect of high-fat feeding has been
reported previously [45]. This is in accordance with our
findings in the HF rats, where all the lipid profiles were
altered significantly [Table 3]. Glucocorticoids have been
reported to induce lipolysis [4,42] causing hyperlipi-
demia. We have observed a similar finding in our study in
the Dex treated [HD or LD] rats [Table 3]. Glucocorticoids
have been reported to induce hyperlipidemia by inhibit-
ing lipoproteins lipase and altering the level/action of
hormone sensitive lipase [56,57] thus it disable the
uptake of FFA by adipose tissue [58]. It have been reported
previously that in the presence of high-caloric diet, corti-
sol affect lipid metabolism adversely [59]. In the HF-HD
and HF-LD rats, due the hyperlipidemic effect of Dex, the
absorbed lipid might not have been stored properly,
which might have leads to increased lipids levels in the
circulation [Table 3].
Glucocorticoids are reported to mediate their effects dif-
ferentially on peripheral vs. central organs, depending on
their concentrations [60]. The effect of Dex have been
reported to be increased when it is administered intracer-
ebroventricularly compared to the same administered
intraperitoneally and the availability of Dex in the central
nervous system is crucial for its effect than its presence in
the peripheral circulation [61]. At the central level, gluco-
corticoids are reported to affect neuronal pathways
involved in the regulation of food intake and energy
expenditure by modulating the hypothalamic neuropep-
tides [59,61] at the periphery, they modulate metabolic
pathways. It was also reported to influence the leptin-
insulin axis [42,62]. The exact mechanism of reduction in
food intake in the HF-HD and HF-LD is not known, but
the hyperlipidemia induced by high-fat feeding might
have potentiated the action/availability of Dex in the cen-
tral nervous system causing reduced food intake in the
HF-HD and HF-LD rats.
Cortisol circulates in the blood in both free and bound
forms; cortisol's biological half-life is around 80 min [40].
In plasma, cortisol is predominantly bound to corticoster-
oid-binding globulin, with a small amount bound loosely
to albumin, and the remainders free [40]. The remaining
free cortisol molecule is lipophilic and has a low molecu-
lar weight [MW ~362 Da], passing from capillaries into
tissues mainly by passive diffusion [40]. The intracellular
and central nervous system availability of glucocorticoids
are controlled by P-glycoprotein [Pgb] and cortisol bind-
ing globulin [CBG] [63,64]. Dietary free fatty acids have
been reported to alter the availability of glucocorticoids
by modulating CBG [64]. CBG is usually saturated in the
upper physiological range of cortisol concentrations, so
that the response of CBG to increasing cortisol level [as
observed in Cushing's syndrome and iatrogenic anti-
inflammatory treatment] is non-linear and have no role in
these situations [24]. The effect of increased level of free
fatty acid on Pgp and its regulation of stereoid transport to
central nervous system are not known. It is possible that
the hyperlipidemia observed in the HF-HD and HF-LD
rats might have altered the steroid-proteins [CBG & Pgp]
interactions which in turn might have altered the availa-
bility of Dex.
Physical state of the membrane is proposed to play major
role in the expression of several genes involved in ageing
& diseases [65]. Fatty acid composition in the diet is one
of the determining factors of membranes' physical state.
Higher amount of saturated fatty acid is reported to alter
the fatty acid composition of membrane, which in turn
affect its fluidity and permeability [18,66]. Hyperlipi-
demia is also proposed to alter the membrane lipid com-
position and its physical state [fluidity], which are
decisive factors in the process of perception and signal
transduction which trigger the expression of several genes
[67]. Moreover, in a normolipidaemic plasma profile, the
distribution of triglycerides, cholesterol and proteins is
optimal for the dissemination of hydrophobic lipids
through the aqueous milieu [36]. When this profile is per-
turbed, the resulting changes are not only detrimental to
the health of an individual, but also provide an alteredInternational Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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environment for drug transport and delivery. Any altera-
tion in drug-protein interactions might shift the propor-
tion of the drug that is available to the tissues, and
potentially affect drug efficacy [36]. And for transport
processes to function efficiently either proper fluidity of
the membrane or correct lipid environment or both are
necessary [67-69].
Lipophilic drugs have a greater tendency to dissolve in the
lipid of the membrane than in the aqueous media bathing
it [37]. There is a linear relationship between the
lipophilicity of drugs and their brain penetration [70,71].
It have been stressed for lipophilic drugs that the mem-
brane drug volume is to be considered instead of "free"
and "bound" concentrations of the drug in the circulation
[72]. Apart from these, steroid hormones are also reported
to alter the structured lipid systems even at physiological
concentrations [73,74] and unbound steroids are trans-
ported across the blood-brain-barrier to enter into the
brain [70,71]. Several drugs such as chlorpromazine,
dibucaine, lignocaine, imipramine, tetracaine and pro-
caine, which are used as psychotropic drugs or local anaes-
thetics, are reported to cause membrane deformation or
fluidization [65].
Further, any changes in lipid profile [caused by obesity,
diet, weight gain, medication or illness] [35-37] values
have been reported to alter the pharmacological of activity
of lipophilic drugs. Pharmacological action of the
lipophilic drug clozapine was reported to be potentiated
by hyperlipidemia. The central nervous system availabil-
ity of this drug was reported to be increased by hyperlip-
diemia, facilitating its penetration across the blood brain
barrier [35]. We have used coconut oil and vanaspati to
induce hyperlipidemia and they are a good source of sat-
urated and trans fatty acids. Severe hyperlipidemia was
also observed in the HF-HD and HF-LD rats compared to
Dex alone treated rats [Table 3]. Dex is also a lipophilic
hormone. All these factors might have facilitated the
increased cellular and central nervous system availability/
action of Dex which in turn might have caused reduced
food intake and metabolic complications in the HF-HD
and HF-LD rats.
Although no direct evidence for the potentiating effect of
hyperlipidemia on Dex in the HF-HD and HF-LD rats is
available, Dex clearance was reported to be increased in
patients taking carbamazapine [75]. Carbazapine treat-
ments reported to alter the lipid metabolism and cause
hyperlipidemia in patients [75,76]. No data was available
correlating the Dex clearance and increased hyperlipi-
demia in these patients.
Reports have shown that the administration of high-fat
induce insulin resistance, which is reported to be medi-
ated by the high level of circulating FFA [77,78]. Similar
findings were observed in the HF rats where the GIR and
insulinogenic index were reduced while lipid values were
increased significantly compared to control rats [Table 2
&3]. It have been reported that the high-fat alone,
although induce insulin resistance, could not produce
diabetes [77,20]. It have also been reported that the role
of free fatty acid in the development of diabetes is a sec-
ondary phenomenon [20]. Our study also shows that
fourteen days of high-fat feeding decreased the insulin
sensitivity [reduced GIR] and insulinogenic index mini-
mally when compared to Dex treated [HD and LD] rats.
Administration of Dex has been reported to induce insu-
lin resistance and hyperglycemia in several animal studies
[41,42]. Similar effects were observed in the HD and LD
rats where the GIR and insulinogenic index were reduced
significantly [Table 2] compared to HF and control rats.
Although the hyperlipidemia was increased significantly
in the HF rats when compared LD rats, the diabetogenic
effect were more pronounced in the LD rats. It have been
reported that lipophilic molecules can passively diffuse
across cell membranes a process that is driven by the con-
centration gradient [40]. The increased level of Dex in the
HD and LD rats might have altered the membrane struc-
ture and enter the cell by concentration gradient which in
turn have caused insulin resistance and impaired glucose
tolerance in the HD and LD rats [Fig. 1 & Table 2]
[70,71,73,74]. The results in the HD and LD rats can be
correlated to exogenous or endogenous elevation of corti-
sol, such as observed in Cushing syndrome.
Increased clearance and intracellular action/availability of
cortisol have been reported in obesity [24,26,27]. The
increased action/availability of cortisol was proposed in
the pathogenesis of insulin resistance, metabolic syn-
drome and type 2 diabetes [23,26-28]. Administration of
hydrocortisone to centrally obese patients reported to
induce severe insulin resistance compared to normal
counterparts [79]. In an animal study administration of a
massive doses of Dex [5 mg/kg for 24 days] to Wistar rats
induced diabetes only in < 20% rats, but in obese Zucker
[fa/fa] rats diabetes was induced in 100% of animals with
a dose of Dex only 4–8% of the used in Wistar rats [80].
In another study, reduction of fat/calorie have been
reported to reduce the insulin resistance caused by dexam-
ethasone in rats [39]. Hyperlipidemia has been reported
to be associated with obesity, metabolic syndrome and its
related disorders. From the results obtained in the HF-HD
and HF-LD rats, it can be speculated that the hyperlipi-
demia might have potentiated the action/availability of
normal or mildly elevated cortisol causing metabolic dis-
orders.International Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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It is further evidenced by the following studies that Knock
out [81] or pharmacological inhibition of the enzyme
11β-HSD1 [82] or rats treated with antiglucocorticoids are
protected from the high-fat diet induced insulin resistance
[83]. These reports indicate that cortisol action is very
essential for high-fat feeding to mediate its metabolic
complications. On the other hand, lowering of free fatty
acid in the circulation reported to prevent the diabe-
togenic effect of cortisol [84,85]. Although both cortisol
and dyslipidemia might be involved in the diabetogenic
process, cortisol might be the primary diabetogen, the
associated/induced hyperlipidemia might involve in the
diabetogenic process by facilitating the intracellular avail-
ability/action of Dex. Elevated cortisol also reported to
increase the hyperlipidemia [56-58], once elevated it may
interact with cortisol forming a vicious cycle.
Asians are quite prone to visceral fat accumulation and
have greater waist circumferences than Europeans [86]
and are prone to develop type 2 diabetes [87]. Altered cor-
tisol metabolism and its aggravation by obesity have been
implicated in the development of metabolic complica-
tions in these populations [88]. Poly cystic ovary syn-
drome is a most common endocrinological disorder of
reproductive age women, 50% of the afflicted women are
obese [89]. Its etiology remains unknown, a variety of the-
ories such as defect at the level of the hypothalamus/pitu-
itary and alteration in the lipid metabolism have been
proposed [89,90]. From our results we can speculate that
either increased cortisol level or altered lipid metabolism
might be the initiating factor of the disease, but it might
be further aggravated by the interaction between the two,
forming a vicious cycle.
Though PCOS affect both obese and lean women, the
metabolic complications are reported to be comparatively
less in the lean women compared to obese [10]. Although
altered function 11 β-HSD1 have been implicated to
explain the difference [10], the role of altered lipid profile
in the obese women compared to lean might have inter-
acted with available cortisol when compared to lean
PCOS patients, in whom the alterations of lipids reported
to be less comparatively[89].
Gestational diabetes is also associated with wide varia-
tions in lipid and cortisol metabolism [9] the interaction
between altered lipid and cortisol might play a role in the
pregnancy induced hyper glycemia. Altered lipid and cor-
tisol metabolism is also associated in several animal mod-
els of metabolic disorders such as db/db, ob/ob mice and
obese Zucker rats [91-93]. Psammomys obesus, the desert rat
is a well-defined animal model for dietary induced insulin
resistance and type 2 diabetes [94]. Seasonal variation cor-
tisol has been reported in these rats [95] but no such sea-
sonal variations were reported in the non-seasonal Wistar
rat, in which the ordinary diet will not induce diabetes
[77]. The interaction between cortisol and lipid metabo-
lism might play a role in the metabolic complications
observed in these rats when fed laboratary diet.
Chronic stress has been reported to promote the con-
sumption of high-caloric food and obesity [96]. Varia-
tions in the macronutrient composition of the diet, such
as high-fat, is reported to affect mood and neuroendo-
crine response to stress [30,97]. Recent report have shown
that macronutrient content of the diet alter the extraadre-
nal regeneration of cortisol [30]. High-energy, particularly
high-fat is reported as a backround form of chronic stress
that elevates cortisol levels. And the high level of cortisol
reported to favor the increased food intake, and at their
periphery alter lipid metabolism forming a vicious cycle
[59,98]. From our results and also from the available
information, we can speculate that the increased availabil-
ity of lipid in the circulation potentiate the action/availa-
bility of cortisol which in turn causes its adverse effects.
Similarly the elevated level of cortisol also might have
altered the lipid metabolism, especially during positive
caloric balance forming a vicious cycle.
Administration Dex have been reported induce several
features characteristics of the neurohormonal response to
stress [39] and it have been correlated to the stress of crit-
ically ill patients [39]. It have been reported that "it is bet-
ter to err on the side of giving too few than too many
calories to patients because, it is likely that infectious and
metabolic complications are increased by overfeeding
[99]. When the administration of Dex have been corre-
lated to the stressful situations of critically ill patients [39]
the same can be extended to other chronic stressful situa-
tion which alter the cortisol secretion. And, though the
amount of fat administered is very high in this study com-
pared to the human consumption it can be considered as
a model for positive caloric balance. Then the outcome of
the results observed in the HF-HD and HF-LD rats indi-
cates that the effect of persistent stress [8] during positive
energy balance [3] might have a pathological role in the
development insulin resistance and its related complica-
tions.
Conclusion
The administration of dexamethasone to high-fat fed rats
have caused severe insulin resistance, hyperglycemia and
hyperlipidemia dose dependently compared to rats
treated dexamethasone of high-fat alone. Hyperlipidemia
induced by high fat feeding might have facilitated the
intracellular availability/action of dexamethasone proba-
bly by altering the membrane fluidity and permeability
and also transport proteins, which in turn might have
caused the insulin resistance and hyperglycemia. High-fat
and dexamethasone induced insulin resistance can beInternational Archives of Medicine 2008, 1:7 http://www.intarchmed.com/content/1/1/7
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used as a new model to study the pathogenesis of type 2
diabetes. As such this study is first and preliminary of its
kind and further studies are warranted.
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